Patents by Inventor LAURA CODARRI-DEAK

LAURA CODARRI-DEAK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATES AND FAP/4-1BB BINDING MOLECULES
    Publication number: 20240092856
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti-CEA/anti-CD3 bispecific antibody.
    Type: Application
    Filed: March 8, 2022
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Laura CODARRI DEAK, Sara COLOMBETTI, Christian KLEIN, Valeria G. NICOLINI, Mario PERRO, Johannes SAM, Christine TRUMPFHELLER, Pablo UMAÑA
  • IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
    Publication number: 20240043535
    Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 8, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Alejandro Carpy Gutierrez Cirlos, Christina Claus, Laura Codarri Deak, Diana Darowski, Tanja Fauti, Claudia Ferrara Koller, Anne Freimoser-Grundschober, Sylvia Herter, Thomas Hofer, Christian Klein, Laura Lauener, Stephane Leclair, Ekkehard Moessner, Christiane Neumann, Pablo Umaña, Ali Bransi, Marlena Surówka
  • Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
    Patent number: 11865082
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: January 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Douglas Hanahan, Christian Klein, Valeria Nicolini, Pablo Umana, Stephan Wullschleger
  • COMBINATION THERAPY EMPLOYING A PD1-LAG3 BISPECIFIC ANTIBODY AND A CD20 T CELL BISPECIFIC ANTIBODY
    Publication number: 20240002546
    Abstract: The invention relates to combination therapies employing anti-PD1/anti-LAG3 bispecific antibody and a CD20 T cell-activating bispecific antibody, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Mario Perro, Patrick Alexander Aaron Weber
  • ANTI-LAG3 ANTIBODIES
    Publication number: 20240002506
    Abstract: The present invention relates to anti-LAG3 antibodies, to methods of producing these molecules and methods of using the same.
    Type: Application
    Filed: June 20, 2023
    Publication date: January 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura CODARRI DEAK, Stefan C. DENGL, Jens FISCHER, Christian KLEIN, Stefan SEEBER, Patrick Alexander Aaron WEBER, Adrian ZWICK
  • IMMUNOCONJUGATES
    Publication number: 20230192795
    Abstract: The present invention generally relates to mutant interleukin-7 polypeptides, immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-7 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the mutant interleukin-7 polypeptides or the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant interleukin-7 polypeptides, immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: April 13, 2021
    Publication date: June 22, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Anne Freimoser-Grundschober, Christian Klein, Laura Lauener, Ekkehard Moessner, Cindy Schulenburg, Pablo Umaña, Eleni Maria Varypataki
  • COMBINATION THERAPY WITH MODIFIED PBMCS AND AN IMMUNOCONJUGATE
    Publication number: 20230181712
    Abstract: The present application provides methods for stimulating an immune response in an individual comprising administering a composition of nucleated cells (e.g., PBMCs) comprising an intracellular exogenous antigen in conjunction with administering an immunoconjugate comprising a variant IL-2 polypeptide and a second polypeptide. The variant IL-2 polypeptide exhibits reduced affinity to the ?-subunit of the IL-2 receptor. The second polypeptide targets a tumor cell or a T cell.
    Type: Application
    Filed: May 10, 2021
    Publication date: June 15, 2023
    Inventors: Pablo UMAÑA, Christian KLEIN, Christine TRUMPFHELLER, Valeria G. NICOLINI, Laura CODARRI DEAK, Scott LOUGHHEAD, Matthew BOOTY
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20230183349
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: March 3, 2023
    Publication date: June 15, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Laura CODARRI DEAK, Stefan DENGL, Sebastian FENN, Jens FISCHER, Guy GEORGES, Christian KLEIN, Viktor LEVITSKI, Valeria LIFKE, Oliver PLOETTNER, Stefan SEEBER, Barbara WEISER, Ildiko WUENSCHE, Adrian ZWICK
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20230143310
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: June 30, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Immunoconjugates
    Publication number: 20230134606
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: June 30, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • Immunoconjugates
    Publication number: 20230071733
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and a bispecific antigen binding molecule that binds to PD-1 and Tim-3. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: June 7, 2022
    Publication date: March 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3
    Publication number: 20220387586
    Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: March 7, 2022
    Publication date: December 8, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Jens Fischer, Sabine Imhof-Jung, Christian Klein, Stefan Seeber, Patrick Alexander Aaron Weber
  • BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3
    Publication number: 20220259314
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 3, 2021
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: LAURA CODARRI-DEAK, GEORG FERTIG, JENS FISCHER, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, MARIO PERRO, JOERG THOMAS REGULA, TILMAN SCHLOTHAUER, STEFAN SEEBER, PABLO UMANA, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Immunoconjugates
    Patent number: 11413331
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 16, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • Bispecific antibodies specifically binding to PD1 and LAG3
    Patent number: 11285207
    Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 29, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Jens Fischer, Sabine Imhof-Jung, Christian Klein, Stefan Seeber, Patrick Alexander Aaron Weber
  • Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
    Publication number: 20220072103
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 10, 2022
    Inventors: Laura CODARRI DEAK, Douglas Hanahan, Christian Klein, Valeria Nicolini, Pablo Umana, Stephen Wullschleger
  • Bispecific antibodies specific for PD1 and TIM3
    Patent number: 11130810
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: September 28, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
  • BISPECIFIC ANTIBODIES COMPRISING AN ANTIGEN-BINDING SITE BINDING TO LAG3
    Publication number: 20200354457
    Abstract: The invention relates to novel antibodies particularly suitable for cancer therapies. The antibodies according to the invention are bispecific or multispecific antibodies and comprise a first antigen binding site that binds to LAG3. The first antigen binding site is an autonomous VH domain.
    Type: Application
    Filed: January 30, 2019
    Publication date: November 12, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Stefan Dengl, Jens Fischer, Thomas Hofer, Laurent Lariviere, Ekkehard Moessner, Stefan Seeber, Pablo Umaña
  • ANTI-LAG3 ANTIBODIES
    Publication number: 20200277372
    Abstract: The present invention relates to anti-LAG3 antibodies, to methods of producing these molecules and methods of using the same.
    Type: Application
    Filed: October 2, 2019
    Publication date: September 3, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura CODARRI DEAK, Stefan C. DENGL, Jens FISCHER, Christian KLEIN, Stefan SEEBER, Patrick Alexander Aaron WEBER, Adrian Zwick
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20190382489
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 19, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK